UK competition watchdog accuses Actavis of 'excessive and unfair pricing'
The UK’s Competition and Markets Authority (CMA) has accused generic drugmaker Actavis UK of breaking competition law by raising the price for hydrocortisone tablets paid by the National Health Service.
Actavis UK has increased the price of 10mg hydrocortisone tablets by over 12,000% compared to the branded version of the drug which was sold by a different company, namely the Merck Sharp & Dohme subsidiary of US pharma giant Merck & Co (NYSE: MRK), prior to April 2008. For example, the amount the NHS was charged for 10mg packs of the drug rose from £0.70 in April 2008 to £88.00 ($109 at current exchange rates) per pack by March 2016.
The company also increased the price of 20mg hydrocortisone tablets by nearly 9,500% compared to the previous branded price, equating to charges to the NHS of £102.74 per pack by March 2016, when it had previously paid £1.07 for the branded drug. De-branded (genericized) drugs are not subject to price regulation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze